Studying Epstein-Barr virus pathologies and immune surveillance by reconstructing EBV infection in mice

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 78, Issue 1, 2013, Pages 259-263

  Yasuda, Tomoharu ^a   Wirtz, Tristan ^a   Zhang, Baochun ^b   Wunderlich, Thomas ^c   Schmidt Supprian, Marc ^d   Sommermann, Thomas ^a   Rajewsky, Klaus ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^d MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 1; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL LINEAGE; CELL PROLIFERATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOSURVEILLANCE; LYMPHANGIOGENESIS; LYMPHOMA; LYMPHOMAGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPECIES DIFFERENTIATION; T LYMPHOCYTE; VIRUS CELL TRANSFORMATION; VIRUS EXPRESSION; ACUTE DISEASE; ANIMAL; B CELL LYMPHOMA; DISEASE MODEL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; VIROLOGY;

ACUTE DISEASE; ANIMALS; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOSUPPRESSION; LYMPHOMA, B-CELL; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VIRAL MATRIX PROTEINS;

EID: 84904875828     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2013.78.020222     Document Type: Article

References (19)

1. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. 1998. EBV persistence in memory B cells in vivo. Immunity 9:395-404.
2. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Kieff E. 2004. Role of NF-κB in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 78: 4108-4119.
3. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. 1998. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9: 405-411.
4. Cannons JL, Tangye SG, Schwartzberg PL. 2011. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol 29: 665-705.
5. Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, Carroll MC, Rajewsky K. 2004. B cell receptor signal strength determines B cell fate. Nat Immunol 5: 317-327.
6. Cohen JI. 2000. Epstein-Barr virus infection. N Engl J Med 343: 481-492.
7. Engel P, Eck MJ, Terhorst C. 2003. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 3: 813-821.
8. Feil R, Wagner J, Metzger D, Chambon P. 1997. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 237:752-757.
9. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
10. Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, Quintanilla-Martinez L, Gewies A, Ruland J, Rajewsky K, et al. 2008. Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis. J Exp Med 205: 1317-1329.
11. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. 1998. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci 95: 11963-11968.
12. Küppers R. 2003. B cells under influence: Transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3: 801-812.
13. Mainou BA, Everly DN Jr, Raab-Traub N. 2005. Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3 K. Oncogene 24: 6917-6924.
14. Morra M, Howie D, Grande MS, Sayos J, Wang N, Wu C, Engel P, Terhorst C. 2001. X-linked lymphoproliferative disease: A progressive immunodeficiency. Annu Rev Immunol 19: 657-682.
15. Reth M. 1989. Antigen receptor tail clue. Nature 338: 383-384.
16. Thorley-Lawson DA. 2001. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 1: 75-82.
17. Wang D, Liebowitz D, Kieff E. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43: 831-840.
18. Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
19. Zhang B, Kracker S, Yasuda T, Casola S, Vanneman M, Homig-Holzel C, Wang Z, Derudder E, Li S, Chakraborty T, et al. 2012. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148: 739-751.